Successful use of ketamine to treat severe depression with suicidality post-COVID-19 – A case report

Every second patient who suffers from COVID-19 experiences is at risk for depression. The treatment of severe depression with suicidal risk is challenging in patients with COVID-19 given the restrictions in access to and safety concerns with the use of electroconvulsive therapy during the COVID pand...

Descripción completa

Detalles Bibliográficos
Autores principales: Meha, Sharma, Suhas, Satish, Rao, Naren P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800325/
https://www.ncbi.nlm.nih.gov/pubmed/36597498
http://dx.doi.org/10.1016/j.psycr.2022.100100
Descripción
Sumario:Every second patient who suffers from COVID-19 experiences is at risk for depression. The treatment of severe depression with suicidal risk is challenging in patients with COVID-19 given the restrictions in access to and safety concerns with the use of electroconvulsive therapy during the COVID pandemic. Although ketamine is effective in treating depression, especially in presence of acute suicidality, to date, there are no reports on ketamine use to treat severe depression in the context of COVID-19. In this case report, we describe the success of ketamine to treat a person with severe depression and suicidality following COVID-19 infection.

Ejemplares similares